Table 2

Effects of capsazepine upon the antiproliferative effects of AEA, 2-AG, and olvanil in C6 glioma cells

Capsazepine	Cell Number (× 10³well⁻¹)
Capsazepine	Control	AEA (3 μM)	2-AG (3 μM)	Olvanil (3 μM)
μM
0	30.8 ± 0.47 [8]	8.3 ± 0.42^2-c [7]	11.1 ± 0.51^2-c [8]	18.3 ± 0.28^2-c [3]
1	28.1 ± 0.89^2-a [7]	18.5 ± 0.70^2-b [9]	28.6 ± 0.14^2-b [4]	18.9 ± 0.40 [4]
5	20.5 ± 0.72^2-b [3]	23.8 ± 1.3^2-b [3]
10	13.7 ± 0.46^2-b [7]	21.2 ± 0.83^2-b [7]	20.1 ± 0.32^2-b [4]	15.1 ± 0.33 [4]

C6 glioma cells were treated daily for 4 days with the concentrations of compounds shown, as described under Experimental Procedures. Shown are means ± S.E.M., with the number of experiments given in brackets. The data with 0 and 1 μM capsazepine are also shown in Fig. 5. Statistical significance was determined using the whole data set (i.e., including the combination of capsazepine and the SR compounds shown in Fig. 5).

↵2-a p < 0.05,
↵2-b p < 0.001 versus the corresponding values for the same AEA/2-AG/olvanil treatment in the absence of capsazepine.
↵2-c p < 0.001 versus the corresponding control values in the absence of capsazepine.